Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

• Main Authors: Apaza Veliz, D. G., Herrera Vera, R. D., Cardenas Abarca, C. A., Oporto Gonzales, C. A., Aguilar Ramírez, C., Vega Ramírez, J. L., Urquizo Baldomero, R. M.
• Format: Conference Proceeding
• Language: English
• Subjects: Cancer; Cancer therapies; Dialysis; EXCRETION; FAILURES; Hemodialysis; Iodine; IODINE 131; Iodine isotopes; KIDNEYS; Medical equipment; Medical personnel; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIATION PROTECTION; RADIOACTIVITY; Radioisotopes; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Therapy; THYROID; Thyroid cancer
• ISSN: 0094-243X; 1551-7616
• DOI: 10.1063/1.4955384

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.